EQT Life Sciences and Advent Life Sciences Invest $44M in Cancer Detection Platform Cyted Health
This article covers the Series B funding round on 1 September 2025 for Cyted Health, a Cambridge-based developer of a minimally invasive diagnostics platform for early detection of oesophageal disease, founded by Marcel Gehrung, raising $44 million (£33 million), led by EQT Life Sciences through its EQT Health Economics strategy with co-leads Advent Life Sciences and the British Business Bank and backing from Morningside and BGF.
What does Cyted Health do?
The product is a minimally invasive diagnostics platform that includes the FDA-cleared EndoSign®, a capsule sponge device for collecting oesophageal cells to enable molecular testing and full oesophageal sampling. It supports diagnostic assays for conditions such as Barrett's oesophagus and oesophageal neoplasia.
Why is Cyted Health useful?
Cyted Health addresses late diagnosis of oesophageal conditions by providing a less invasive method for obtaining oesophageal cell samples to enable earlier detection and monitoring. This responds to clinical gaps where fewer than 10% of patients with the precursor condition have a prior diagnosis and only one in five people with oesophageal cancer survive their diagnosis.
How much did Cyted Health raise?
Cyted Health raised $44 million (£33 million) in a Series B round led by EQT Life Sciences, with co-leads Advent Life Sciences and the British Business Bank, to fund US expansion and further clinical validation of its FDA-cleared EndoSign device.
Who invested in Cyted Health?
Key investors in the deal included:
- EQT Life Sciences, a European life sciences investor, is known for backing late-stage healthcare companies across Europe and the United States.
- Specialising in therapeutics and medical technologies, Advent Life Sciences has a strong track record of scaling clinical-stage companies.
- The British Business Bank acts as the UK’s economic development bank, supporting small and medium-sized enterprises through targeted investment programmes.
- Known for a long history in life sciences, Morningside invests globally with a notable presence in Asia and the United States.
- Providing growth capital across the UK and Ireland, BGF backs scaling companies across a range of sectors.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Who founded Cyted Health?
The founders of Cyted Health are Marcel Gehrung (CEO and Co‑founder).
Where is Cyted Health based?
Cyted Health is based in Cambridge, UK.
What sector is Cyted Health in?
Cyted Health operates in the **diagnostics** sector, specialising in gastrointestinal and oncology diagnostics. This sector matters now because there is growing emphasis on **early cancer detection** and increasing private and public investment to scale clinically validated tests for wider adoption. Regulatory clearances and cross‑border expansion are accelerating commercial opportunities.
Key trends and challenges are concise. There is a shift to minimally invasive, patient‑friendly sampling and molecular assays. Fundraising and strategic partnerships are enabling rapid expansion. Large clinical validation studies remain necessary for widespread adoption. Quick examples:
- FDA clearance of EndoSign®
- Ongoing DETECT‑ME clinical validation study
- Recent Series B funding supporting US expansion
Scale of the opportunity is significant. Recent funding raised: **$44 million**. Global annual oesophageal cancer incidence is about **600,000** new cases, highlighting substantial unmet need for earlier detection.
For a deeper look at innovation in this space, see the healthtech startups in the UK.
They've invested in Cyted Health
Get to know these healthtech investors
Click here for a full list of 7,526+ startup investors in the UK